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EM  Advances 

Dilute  proparacaine  for  the  management  of  acute 
corneal  injuries  in  the  emergency  department 
Ian  Michael  Ball,  MD;*  Jamie  Seabrook,  MA;†  Nimesh  Desai,  BSc(Pharm),  MD;‡  Larry  Allen,  MD;‡ 
Scott  Anderson,  MD* 
ABSTRACT 
Objective:  Dogma  discourages  the  provision  of  topical  anes
thetics  to  patients  with  corneal  injuries  discharged  from  the 
emergency  department  because  of  the  toxicity  of  concen
trated  solutions.  We  compared  the  analgesic  efficacy  of  dilute 
topical  proparacaine  with  placebo  in  emergency  department 
patients  with  acute  corneal  injuries. 
Methods:  We  conducted  a  prospective  randomized  controlled 
trial  of  adults  with  corneal  injuries  presenting  to  one  of  2  tertiary 
care  emergency  departments  in  London,  Ont.  Patients  were  ran
domly  assigned  to  groups  receiving  either  0.05%  proparacaine 
or  placebo  drops  as  outpatients  and  were  followed  up  to  heal
ing  by  a  single  ophthalmologist.  Our  primary  outcome  was  pain 
reduction  as  measured  on  a  10cm  visual  analog  scale. 
Results:  Fifteen  participants  from  the  proparacaine  group  and 
18  participants  from  the  placebo  group  completed  the  study. 
The  mean  age  of  the  patients  was  38.7  (standard  deviation 
12.3)  years  and  the  majority  were  male  (85%).  Pain  reduction 
was  significantly  better  in  the  proparacaine  group  than  in  the 
placebo  group,  with  a  median  improvement  of  3.9  (interquar
tile  range  [IQR]  1.5–5.1)  cm  on  the  visual  analog  scale  versus  a 
median  improvement  of  0.6  (IQR  0.2–2.0)  cm  (p  =  0.007).  The 
proparacaine  group  was  more  satisfied  (median  level  of  satis
faction  8.0  [IQR  6.0–9.0]  cm  on  a  10cm  visual  analog  scale  v. 
2.6  [IQR  1.0–8.0]  cm,  p  =  0.027).  There  were  no  ocular  compli
cations  or  signs  of  delayed  wound  healing  in  either  group. 
Conclusion:  Dilute  topical  proparacaine  is  an  efficacious  anal
gesic  for  acute  corneal  injuries.  Although  no  adverse  events 
were  observed  in  our  study  population,  larger  studies  are 
required  to  evaluate  safety. 

toxicité  des  solutions  concentrées.  Nous  avons  comparé  l’effi
cacité  analgésique  de  la  proparacaïne  diluée  appliquée  locale
ment  à  celle  d’un  placebo  chez  des  patients  s’étant  présentés 
à  l’urgence  avec  des  lésions  cornéennes  aiguës. 
Méthodes  :  Nous  avons  réalisé  un  essai  contrôlé  randomisé 
prospectif  auprès  d’adultes  ayant  des  lésions  cornéennes  et 
s’étant  présentés  à  l’un  des  deux  services  d’urgence  d’un  cen
tre  hospitalier  de  soins  tertiaires  à  London,  en  Ontario.  Les 
patients  ont  été  répartis  au  hasard  entre  des  groupes  recevant 
dans  une  clinique  externe  soit  de  la  proparacaïne  à  0,05  %, 
soit  des  gouttes  d’un  placebo.  Ils  ont  été  suivis  jusqu’à  la 
guérison  par  un  seul  ophtalmologiste.  Notre  principal  critère 
d’évaluation  était  la  réduction  de  la  douleur,  mesurée  sur  une 
échelle  visuelle  analogique  (EVA)  de  0  à  10  cm. 
Résultats  :  Quinze  participants  du  groupe  proparacaïne  et  18 
du  groupe  placebo  ont  terminé  l’étude.  L’âge  moyen  des 
patients  était  de  38,7  ans  (écarttype  de  12,3)  et  la  majorité 
était  de  sexe  masculin  (85  %).  La  réduction  de  la  douleur  était 
significativement  meilleure  dans  le  groupe  proparacaïne  que 
dans  le  groupe  placebo,  avec  une  amélioration  médiane  de 
3,9  cm  (intervalle  interquartile  [IIQ]  de  1,5  à  5,1)  sur  l’EVA  par 
rapport  à  une  amélioration  médiane  de  0,6  cm  (IIQ  de  0,2  à 
2,0,  p  =  0,007).  Le  groupe  proparacaïne  était  plus  satisfait  des 
résultats  (niveau  de  satisfaction  médian  de  8,0  cm  [IIQ  de  6,0 
à  9,0])  sur  l’EVA  contre  2,6  cm  [IIQ  de  1.0  à  8,0],  p  =  0,027). 
Aucune  complication  oculaire  ou  aucun  signe  de  retard  de 
cicatrisation  n’ont  été  notés  dans  les  deux  groupes. 
Conclusion  :  La  proparacaïne  diluée  appliquée  localement  est 
un  analgésique  efficace  pour  les  lésions  cornéennes  aiguës. 
Bien  qu’aucun  effet  indésirable  n’ait  été  observé  dans  cette 
population  d’étude,  des  études  de  plus  grande  envergure 
s’imposent  pour  évaluer  l’innocuité. 

Keywords:  proparacaine,  pain,  cornea,  abrasion 

RÉSUMÉ 

INTRODUCTION 

Objectif  :  Le  dogme  déconseille  aux  médecins  de  remettre 
aux  patients  présentant  des  lésions  cornéennes  des  anes
thésiques  topiques  à  leur  sortie  de  l’urgence,  en  raison  de  la 

Acute  corneal  injuries  are  a  common  complaint  in  the 
emergency  department.  They  cause  significant  patient 
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morbidity,  including  pain,  loss  of  sleep  and  missed 
work.  The  approach  to  pain  management  varies  in  this 
patient  population  and  includes  the  following:  no  anal
gesia,  oral  or  topical  nonsteroidal  antiinflammatory 
drugs  (NSAIDs),  oral  opiates  and  cycloplegics.1  Topical 
agents  can  reduce  pain;  however,  their  use  must  be  lim
ited.  Topical  NSAIDs  have  induced  sterile  corneal  infil
trates.2  Textbooks  state  that  prolonged  topical  applica
tion  of  local  anesthetics  is  contraindicated3,4  because  of 
their  inhibition  of  mitosis  and  cellular  migration.5  Local 
anesthetics  are  said  to  impair  the  ability  of  the  corneal 
epithelium  to  oxidize  glucose  and  pyruvate.5  Topical 
anesthetics  can  markedly  decrease  corneal  sensation  to 
touch,  which  is  an  important  corneal  protective  mecha
nism.6  At  commonly  encountered  concentrations  (e.g., 
0.5%  proparacaine),  these  agents  are  also  directly  toxic 
to  the  cornea  with  prolonged  and  repeated  use,5,7–9  caus
ing  increased  corneal  thickness,  opacification,  stromal 
infiltration  and  punctate  epithelial  defects.10–12 
Several  publications  in  the  ophthalmology  literature 
have  reported  that  the  outpatient  use  of  more  dilute 
topical  anesthetics  is  safe  and  effective  after  photo
refractive  surgery.13–15  We  asked  whether  dilute  0.05% 
proparacaine  applied  topically  would  be  efficacious  in 
patients  with  acute  corneal  injuries  discharged  from  the 
emergency  department.  Our  primary  outcome  was  pain 
reduction  from  baseline  as  measured  on  a  10cm  visual 
analog  scale.  Secondary  end  points  included  patient  sat
isfaction  with  the  study  drug,  use  of  medications  for 
breakthrough  pain,  and  signs  of  delayed  wound  healing 
or  corneal  toxicity  on  followup. 
METHODS 

Design 
We  performed  a  prospective  randomized  doubleblind 
placebocontrolled  trial  on  adults  with  corneal  injuries. 
Setting  and  study  population 
Our  study  was  performed  at  2  tertiary  care  emergency 
departments  in  London,  Ont.,  with  a  combined  census 
of  approximately  120  000  visits  per  year.  We  enrolled 
a  convenience  sample  of  adult  patients  during  an 
8month  period  beginning  in  October  2005.  Patients 
were  excluded  if  they  had  any  of  the  following:  inability 
to  consent  to  the  study,  allergy  to  any  of  the  study  med
ications,  inability  to  attend  followup  appointments  for 
any  reason,  or  previous  eye  injury  or  pathology. 
390 
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Interventions 
Patients  were  randomly  assigned  to  groups  receiving 
either  0.05%  proparacaine  or  a  colour and  smell
matched  placebo.  The  usual  singledose  topical  anes
thetic  used  to  facilitate  eye  examination  in  the  partici
pating  emergency  departments  is  0.5%  proparacaine. 
Our  pharmacy  diluted  this  usual  medication  10fold, 
emulating  a  previous  postoperative  study. 15  Patients 
were  instructed  to  use  2  to  4  drops  of  the  study  drug  on 
an  asneeded  basis  for  the  next  7  days.  No  minimum 
time  interval  between  dosing  was  stipulated,  allowing 
patients  unlimited  use  of  the  study  drug.  A  total  volume 
of  40  mL  was  dispensed  to  each  patient. 
Participants  were  given  a  pain  log,  topical  fluoro
quinolone  and  tablets  of  325  mg  acetaminophen  with 
30  mg  of  codeine  for  breakthrough  pain.  Patients 
received  an  instruction  sheet  explaining  how  to  use  the 
pain  logs  as  well  as  an  information  sheet  explaining  the 
goals  of  the  trial.  All  patients  included  in  the  study 
were  prescribed  topical  gatifloxacin,  1–2  drops  every 
2  hours  to  the  affected  eye  while  awake  for  the  dura
tion  of  the  study  period.  They  were  instructed  to  take  1 
to  2  tablets  of  the  acetaminophen  with  codeine  every 
4  hours  if  needed.  Patients  were  asked  to  record  their  use 
of  oral  analgesics,  and  to  bring  all  unused  pills  to  clinic 
followup  appointments,  where  they  were  counted. 
Outcome  measures 
Participants  were  asked  to  complete  the  visual  analog 
scale16  describing  their  pain  immediately  before,  and 
5  minutes  after  selfadministration  of  the  study  drug. 
On  the  10cm  scale,  0  indicated  “no  pain”  and  10  indi
cated  “the  worst  imaginable  pain.”  The  pre and  post
drug  visual  analog  scales  were  printed  on  the  same  sheet 
of  paper,  allowing  the  participant  to  see  both  scales  at 
the  time  of  scoring.  The  primary  outcome  was  the 
mean  difference  in  pain  scores  before  and  after  drug 
administration  as  recorded  by  each  study  participant. 
Satisfaction  was  recorded  by  participants  using  a  separate 
10cm  visual  analog  scale  (0  =  completely  unsatisfied, 
10  =  completely  satisfied). 
All  patients  attended  for  followup  at  an  outpatient 
clinic  on  days  1,  3  and  5  after  enrolment  by  a  single  oph
thalmologist,  who  was  unaware  of  the  patient  allocation. 
The  ophthalmologist  was  directed  to  identify  signs  of 
delayed  wound  healing,  increased  corneal  thickness, 
corneal  opacification,  new  corneal  epithelial  defects  or 
any  other  ocular  pathology  that  could  be  related  to 
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either  the  initial  injury  or  the  use  of  study  medication. 
Patients  made  additional  visits  thereafter  at  the  discre
tion  of  the  observing  ophthalmologist.  At  the  final  oph
thalmology  clinic  visit,  the  pain  logs  were  collected. 

Ethics 
Patients  provided  written  consent  to  the  emergency 
physician  at  the  time  of  enrolment  as  approved  by  our 
institution’s  research  ethics  board. 

Patient  recruitment 
Statistical  analysis 
The  attending  emergency  physician  and  emergency 
medicine  residents  on  duty  recruited  patients  into  the 
study.  The  total  number  of  patients  eligible  for  inclu
sion  in  the  trial  during  the  8month  trial  period  was  not 
recorded.  No  attempt  was  made  to  measure  the  severity 
of  the  corneal  injury,  either  in  the  emergency  depart
ment  or  at  followup. 
Randomization  and  concealment 
Staff  at  the  hospital  pharmacy  diluted  the  proparacaine 
and  filled  numbered  vials  with  either  proparacaine  or 
placebo.  These  vials  were  distinguishable  only  by  num
ber.  The  randomization  key  was  generated  via  a  com
puter  using  the  random  number  function  of  Excel 
(Microsoft).  The  lead  author  and  pharmacist  were  the 
only  2  people  with  access  to  the  randomization  key. 
The  randomization  key  was  made  available  to  the  lead 
author  only  after  study  completion.  The  contents  of 
the  study  drug  vial  were  concealed  from  all  personnel 
involved  in  patient  care,  as  well  as  from  the  patients 
themselves.  Treating  physicians  were  instructed  to 
select  the  next  available  vial  to  dispense  to  the  partici
pant  at  the  time  of  enrolment.  The  allocation  was  con
firmed  by  inspection  of  the  numbered  vial  at  followup. 

Data  were  analyzed  using  SPSS,  version  15.0  (SPSS 
Inc.).  Data  are  reported  as  means  and  standard  devia
tions  for  normally  distributed  continuous  variables,  or 
medians  and  interquartile  ranges  (IQRs)  for  skewed 
continuous  variables.  Percentages  were  used  for  cate
gorical  variables.  The  Mann–Whitney  test  was  used  to 
compare  differences  in  pain  reduction,  drug  satisfaction 
and  number  of  oral  tablets  taken  between  the  groups. 
Sample  size 
We  determined  that  16  participants  in  each  group  would 
be  needed  to  have  an  80%  chance  of  detecting  a  pain 
reduction  of  2  cm  on  the  visual  analog  scale  between  the 
2  groups,  assuming  an  ∇  of  0.05,  and  a  standard  devia
tion  of  2  cm.  We  chose  2  cm  to  represent  a  clinically 
meaningful  difference  based  on  an  informal  survey  of 
attending  emergency  physicians  at  our  hospital. 
RESULTS 

Fifteen  participants  from  the  proparacaine  group  and 
18  participants  from  the  placebo  group  completed  the 
study.  Eight  enrolled  patients  either  did  not  use  even  a 

Table 1. Outcomes of patients with corneal injuries who received proparacaine (n  = 15) or
placebo (n  = 18) drops on release from hospital
Group; median (IQR)
Variable
Patient age, yr
Pain reduction,† cm
Patient satisfaction,‡ score
Interval,§ min
Drops administered¶
Tablets of acetaminophen
with codeine taken**

Proparacaine

Placebo

p  value*

38.0 (28.0–47.0)
3.9
(1.5–5.1)
8.0
(6.0–9.0)
192.5 (126.0–245.0)
7.5
(3.0–9.0)
0.0
(0.0–2.0)

39.3 (27.0–46.0)
0.6
(0.2–2.0)
2.6
(1.0–8.0)
170.0 (120.0–246.0)
5.0
(3.0–6.0)
2.0
(0.0–5.0)

0.94
0.007
0.027
0.80
0.17
0.22

IQR = interquartile range.
*Wilcoxon rank sum test.
†Pain reduction as recorded by patients on a 10-cm visual analog scale.
‡Patient satisfaction with the efficacy of study drug recorded by patients at the end of the study, where 0 = not satisfied at all and
10 = completely satisfied.
§Median time interval between administration of the first and last drop of study drug for each time the study drug was used.
¶The median number of drops of the study drug that patients self-administered each time the study drug was used.
**The median number of tablets of acetaminophen (300 mg) with codeine (30 mg) used after administration of the study drug.
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Fig.  2.  The  diamonds  represent  the  satisfaction  scores  for  each 
study  participant.  The  upper  and  lower  borders  of  each  rectan
gle  represent  the  75th  and  25th  percentiles  of  patient  satisfac
tion.  The  horizontal  line  within  each  rectangle  represents  the 
median  patient  satisfaction.  VAS  =  visual  analog  scale. 
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DISCUSSION 

Many  physicians  receive  requests  from  patients  for  a 
topical  anesthetic  prescription  after  the  initial  dose 
administered  in  the  emergency  department  provides 
complete  relief.  Dogma  instructs  us  to  never  prescribe 
outpatient  topical  anesthesia  for  corneal  injuries. 
The  findings  of  this  study  were  consistent  with  those 
of  3  similar  studies  in  the  ophthalmology  literature. 
Each  study  found  that  brief  outpatient  use  of  dilute  top
ical  anesthetic  was  safe  and  effective  as  an  analgesic.13–15 
The  clinically  significant  differences  in  pain  reduction 
and  patient  satisfaction  in  our  study  demonstrate  the 
efficacy  of  diluted  proparacaine. 

Overall satisfaction (VAS, cm)

single  dose  of  medication,  did  not  record  their  pain  in 
their  pain  logs  or  were  lost  to  followup.  These  patients 
were  removed  from  the  trial  entirely,  and  were  not 
included  in  an  intent  to  treat  fashion. 
The  mean  age  in  the  proparacaine  group  was  38.0 
years,  and  in  the  placebo  group  was  39.3  years.  In  the 
proparacaine  group,  87%  of  participants  were  male,  and 
in  the  placebo  group  83%  were  male.  All  injuries  were 
caused  by  trauma  that  had  occurred  within  24  hours  of 
presentation  to  the  emergency  department. 
Table  1  shows  patient  outcomes  between  the  2 
groups.  Pain  reduction  5  minutes  after  administration  of 
the  study  drug  was  significantly  better  in  the  propara
caine  group  than  in  the  placebo  group  (Fig.  1)  (median 
improvement  3.9  [IQR  1.5–5.1]  cm  on  the  visual  analog 
scale  v.  0.6  [IQR  0.2–2.0]  cm,  p  =  0.007).  The  propara
caine  group  was  also  much  more  satisfied  (Fig.  2) 
(median  level  of  satisfaction  8.0  [IQR  6.0–9.0]  cm  v.  2.6 
[IQR  1.0–8.0]  cm,  p  =  0.027).  The  placebo  group  took 
more  acetaminophen  with  codeine  tablets  (median  2.0 
[IQR  0.0–5.0]  tablets)  than  the  proparacaine  group 
(median  0.0  [IQR  0.0–2.0]  tablets)  but  this  difference 
was  not  statistically  significant  (Fig.  3)  (p  =  0.22). 
There  was  no  difference  in  frequency  of  administra
tion  of  the  study  drug  between  the  2  groups  based  on 
pain  logs.  There  were  also  no  ocular  complications  or 
evidence  of  delayed  wound  healing  in  either  group. 

6

4

9

6

2
3
0
Proparacaine

Control
0

Study group

Control

Proparacaine

Study group

Fig.  1.  Reduction  in  pain  5  minutes  after  drop  application. 
The  ∆  between  the  mean  pain  score  before  administration  of 
the  study  drug,  and  the  mean  pain  score  5  minutes  after 
administration  is  shown  for  each  participant.  The  diamonds 
represent  the  mean  ∆  pain  scores  for  each  study  participant. 
The  upper  and  lower  borders  of  each  rectangle  represent 
the  75th  and  25th  percentiles  of  mean  pain  reduction.  The 
horizontal  line  within  each  rectangle  represents  the  median 
pain  reduction.  VAS  =  visual  analog  scale. 
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Fig.  3.  Rescue  doses  of  oral  analgesia.  The  diamonds  repre
sent  the  mean  number  of  tablets  of  acetaminophen  with 
codeine  used  by  each  patient  after  each  use  of  the  study 
drug.  The  upper  and  lower  borders  of  each  rectangle  re
present  the  75th  and  25th  percentiles  of  mean  number  of 
tablets  used  per  patient.  The  horizontal  line  within  each  rec
tangle  represents  the  median  of  the  mean  number  of  tablets 
used  per  patient. 
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Although  there  was  a  similar  time  to  pain  relief  in 
both  groups  among  the  patients  who  achieved  pain 
relief,  a  small  number  of  patients  in  the  placebo  group 
continued  to  use  rescue  oral  acetaminophen  with 
codeine  tablets  for  a  longer  period. 
The  literature  provides  examples  of  corneal  toxicity 
from  repeat  application  of  concentrations  of  anesthetic 
intended  for  1time  dosing,10–12  generally  on  the  order  of 
10  times  greater  than  the  concentration  that  we  used. 
Such  toxicity  has  also  been  described  with  injected 
0.75%  bupivacaine,  4%  lidocaine,  0.5%  proparacaine 
and  0.5%  tetracaine  in  rabbits.17  This  same  rabbit  study 
supports  the  safety  of  dilute  injected  anesthetic  agents. 
An  abundance  of  evidence  exists  for  the  toxicity  of  topi
cal  anesthetic  when  abused.18–24  We  did  not  observe  any 
evidence  of  harm  from  dilutestrength  topical  anes
thetic  used  for  a  prescribed  duration. 
Patients  in  our  study  were  encouraged  to  use  the 
drops  as  frequently  as  needed.  Despite  the  liberal  pre
scription  of  the  study  drug,  both  groups  administered 
most  of  their  drops  during  the  first  24  hours.  We  specu
late  that  patients  in  the  study  drug  arm  achieved  ade
quate  analgesia  quickly,  and  did  not  require  much 
further  analgesic  use.  Should  such  patients  require  anal
gesia  for  only  24  to  36  hours,  clinicians  could  prescribe 
smaller  volumes  of  anesthetic  for  a  shorter  duration, 
which  may  further  improve  safety. 
The  use  of  prophylactic  topical  antibiotics  in  the 
uncomplicated  corneal  injury  is  controversial  and  not 
standard  practice  in  our  emergency  departments.  We 
added  topical  antibiotics  in  consultation  with  ophthal
mology  colleagues  who  participated  in  the  study. 
Although  our  study  found  no  evidence  of  harm  from 
proparacaine,  our  patients  were  dispensed  a  limited  vol
ume  of  dilute  anesthetic.  Nonetheless,  at  the  end  of  5–7 
days,  all  of  our  patients  showed  evidence  of  appropriate 
injury  healing  and  no  patient  had  continued  pain. 
Limitations 
This  study  was  performed  at  a  single  centre  and  en  
rolled  a  small  number  of  patients.  It  was  not  powered 
for  important  safety  outcomes.  We  had  hoped  to  enrol 
consecutive  patients  but  suspect  that  recruiting  physi
cians  missed  many  eligible  patients.  No  attempt  was 
made  to  measure  the  severity  or  the  cause  of  the  corneal 
injury.  We  did  attempt  to  verify  patient  compliance  with 
our  protocol  by  counting  remaining  tablets,  but  we  did 
not  attempt  to  measure  volume  of  study  drug  remaining 
at  followup. 

CONCLUSION 

Dilute  topical  anesthetic  is  an  efficacious  analgesic  in 
patients  with  corneal  injuries  discharged  from  the  emer
gency  department.  Treatment  with  dilute  topical  anes
thetics  may  be  effective  and  safe  when  prescribed  for 
1  to  2  days.  Larger  studies  powered  for  safety  are  neces
sary  before  widespread  adoption  of  this  practice. 
Competing  interests:  None  declared. 
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Important Safety Information
EpiPen® and EpiPen® Jr Auto-injectors are indicated for the emergency
treatment of anaphylactic reactions in patients who are determined to
be at increased risk for anaphylaxis, including individuals with a history
of anaphylactic reactions. They are intended for immediate selfadministration for the emergency treatment of severe allergic reactions
(Type I), including anaphylaxis associated with foods, stinging and
biting insects, medications, latex, other allergens, and for idiopathic and
exercise-induced anaphylaxis. Selection of the appropriate dosage
strength is determined according to patient body weight.
There are no absolute contraindications to the use of epinephrine in a
life-threatening allergic situation. Epinephrine use should be avoided in
patients with cardiogenic, traumatic, or hemorrhagic shock; cardiac
dilation; and/or cerebral arteriosclerosis. Epinephrine use should be
avoided in patients with organic brain damage and in patients with
narrow-angle glaucoma. Administer with caution to elderly or
hyperthyroid individuals, pregnant women, and individuals with
cardiovascular disease or diabetes.
Adverse reactions of epinephrine include transient, moderate anxiety;
feelings of over stimulation; apprehensiveness; restlessness; tremor;
weakness; shakiness; dizziness; sweating; tachycardia; palpitations;
pallor; nausea and vomiting; headache; and/or respiratory difficulties.
EpiPen® and EpiPen® Jr Auto-injectors are designed as emergency
supportive therapy only. They are not a replacement or substitute for
subsequent medical or hospital care, nor are they intended to supplant
insect venom hyposensitization.

